AFT Pharmaceuticals looks ahead to Maxigesic US licensing windfall

David Flacks says the fact that Maxigesic pain relief medicine has been approved for sale by the US Food and Drug Administration in a first for NZ. (Image: AFT Pharmaceuticals)

Staff reporters

Fri, 04 Aug 2023

AFT Pharmaceuticals is expecting at least $6 million in licensing income from the United States launch of its Maxigesic patented pain-relief medicine, but isn’t yet sure when that will come in.The dual New Zealand and Australian stock market-listed pharmaceutical company told its annual shareholder meeting on Aug 4 that the licensing income for its Maxigesic IV medicine could arrive near the end of the March 31, 2024, financial year or early in the 2025 year.Chair David Flacks said a prescription-only version of AFT's Maxigesic p...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.

Name {{ registerForm.errors.get('name') }}

Email address {{ registerForm.errors.get('email') }}

Phone Number {{ registerForm.errors.get('phone') }}

Job Title {{ registerForm.errors.get('title') }}

Password Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Repeat password {{ registerForm.errors.get('password_confirmation') }}

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Credit Card

Cardholder's name

{{ __(plans[index].name) | capitalize }} {{ plans[index].attributes.old_price | currency }} {{ plans[index].price | currency }}

All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service

{{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}